NeuroBo Pharmaceuticals Inc. reported that the previously announced merger between NeuroBo Pharmaceuticals Inc. and Gemphire Therapeutics closed on December 31, 2019. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker NRBO on December 31, 2019. NeuroBo will focus on advancing the company's clinical-stage pipeline for neurodegenerative diseases.

The combined organization will operate under the leadership of NeuroBo's new President and Chief Executive Officer, Richard J. Kang, Ph.D., and Chief Medical Officer, Mark Versavel, M.D., Ph.D., MBA. The board of directors of the combined organization is comprised of seven directors: two directors from the former NeuroBo board, one director from the former Gemphire board and four newly appointed members designated by NeuroBo prior to the merger. Ms. Na Yeon (Irene) Kim, M.S., MBA, was appointed as chairman of the board.